CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
FARAPULSE Pulsed Field Ablation Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05493852
NCT05493852N/ACompleted

A Real-world Study of the FARAPULSE Pulsed Field Ablation System in A Chinese Population With Paroxysmal Atrial Fibrillation

Boston Scientific Corporation·observational·Posted Aug 9, 2022·Updated Jan 31, 2025

In Brief

An observational study evaluating FARAPULSE Pulsed Field Ablation System for Paroxysmal Atrial Fibrillation. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The real world study is a retrospective and/or prospective, single-center, single-arm observational study to observe the safety and effectiveness of the FARAPULSE Pulsed Field Ablation System for treatment of recurrent, symptomatic Paroxysmal Atrial Fibrillation (PAF) in a Chinese population.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedAug 9, 2022
Enrollment StartFeb 24, 2023
Primary CompletionAug 21, 2023
Study CompletionJul 10, 2024
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 3.9 years ago

Interventions

FARAPULSE Pulsed Field Ablation Systemdevice

Patients diagnosed as paroxysmal atrial fibrillation with indication of ablation will be treated by FARAPULSE Pulsed Field Ablation System.